AVITA Medical, Inc. (RCEL)

Revenue by Product

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Jun 30, 2021	Jun 30, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017
Commercial	64.02M
Commercial Growth	28.62%
Biomedical Advanced Research and Development Authority Revenue for Right of First Access	195.00K
Biomedical Advanced Research and Development Authority Revenue for Right of First Access Growth	-41.79%
Deferred Commercial	33.00K
Deferred Commercial Growth	0%

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Jun 30, 2021	Jun 30, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017
United States	62.16M
United States Growth	34.08%
Japan	1.43M
Japan Growth	-57.54%
Australia	312.00K
Australia Growth	40.54%
United Kingdom	196.00K
United Kingdom Growth	39.01%
European Union	155.00K
European Union Growth	203.92%